Life Md, Inc. LFMD
We take great care to ensure that the data presented and summarized in this overview for LifeMD, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LFMD
View all-
Black Rock Inc. New York, NY2.34MShares$12.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.7MShares$9.35 Million0.0% of portfolio
-
Divisadero Street Capital Management, LP Miami, FL1.51MShares$8.28 Million1.07% of portfolio
-
State Street Corp Boston, MA1.16MShares$6.34 Million0.0% of portfolio
-
B. Riley Securities, Inc. Los Angeles, CA1.08MShares$5.94 Million0.46% of portfolio
-
Royce & Associates LP901KShares$4.95 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA819KShares$4.5 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.766KShares$4.2 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny757KShares$4.15 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT687KShares$3.77 Million0.01% of portfolio
Latest Institutional Activity in LFMD
Top Purchases
Top Sells
About LFMD
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
Insider Transactions at LFMD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 11
2024
|
Stefan Galluppi Chief Innovation Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+6.19%
|
$12,000
$4.93 P/Share
|
Aug 18
2024
|
Dennis Wijnker Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+44.44%
|
-
|
Jul 17
2024
|
Piyush Jindal Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,835
+6.41%
|
-
|
Apr 26
2024
|
Calum Archibald Macrae Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+50.0%
|
-
|
Apr 04
2024
|
Naveen Bhatia Director |
BUY
Acquisition or disposition by will or laws
|
Direct |
500
+0.1%
|
-
|
Mar 21
2024
|
Eric Harold Yecies General Counsel & CCO |
BUY
Grant, award, or other acquisition
|
Direct |
56,250
+17.18%
|
-
|
Mar 21
2024
|
Maria E. Stan Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+41.56%
|
-
|
Mar 21
2024
|
Stefan Galluppi Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+41.41%
|
-
|
Mar 21
2024
|
Marc David Benathen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+19.86%
|
-
|
Mar 21
2024
|
Nicholas P Alvarez Chief Acquisition Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+15.63%
|
-
|
Mar 13
2024
|
Naveen Bhatia Director |
BUY
Acquisition or disposition by will or laws
|
Direct |
750
+0.15%
|
-
|
Nov 13
2023
|
Justin Schreiber Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+1.7%
|
-
|
Nov 06
2023
|
Piyush Jindal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+10.0%
|
$75,000
$2.52 P/Share
|
Aug 31
2023
|
Bertrand Velge Director |
BUY
Open market or private purchase
|
Indirect |
60,000
+14.65%
|
$180,000
$3.93 P/Share
|
Aug 30
2023
|
Bertrand Velge Director |
BUY
Open market or private purchase
|
Indirect |
40,000
+12.14%
|
$120,000
$3.76 P/Share
|
Aug 29
2023
|
Bertrand Velge Director |
BUY
Open market or private purchase
|
Indirect |
32,072
+11.39%
|
$96,216
$3.58 P/Share
|
Aug 25
2023
|
John R Strawn Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+13.04%
|
-
|
Aug 21
2023
|
Roberto Simon Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+33.33%
|
-
|
Jul 28
2023
|
Alexander Mironov President |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+28.59%
|
-
|
Jul 12
2023
|
Nicholas P Alvarez Chief Acquisition Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+31.25%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 378K shares |
---|---|
Open market or private purchase | 3K shares |
Acquisition or disposition by will or laws | 1.25K shares |